Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$40.25 - $52.99 $360,760 - $474,949
8,963 New
8,963 $372,000
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $6,371 - $7,073
-100 Reduced 2.55%
3,829 $245,000
Q1 2023

May 16, 2023

BUY
$65.71 - $74.53 $57,167 - $64,841
870 Added 28.44%
3,929 $272,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $59,577 - $70,548
-870 Reduced 22.14%
3,059 $220,000
Q3 2021

Oct 22, 2021

SELL
$59.17 - $69.31 $37,277 - $43,665
-630 Reduced 13.82%
3,929 $232,000
Q4 2020

Feb 26, 2021

SELL
$57.74 - $65.43 $282,579 - $320,214
-4,894 Reduced 51.77%
4,559 $283,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $28,140 - $31,183
490 Added 5.47%
9,453 $607,000
Q2 2020

Aug 18, 2020

SELL
$54.82 - $64.09 $26,861 - $31,404
-490 Reduced 5.18%
8,963 $527,000
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $74,061 - $96,605
1,505 Added 18.94%
9,453 $607,000
Q3 2019

Nov 15, 2019

SELL
$42.77 - $50.71 $21,385 - $25,355
-500 Reduced 5.92%
7,948 $403,000
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $36,588 - $40,458
820 Added 10.75%
8,448 $383,000
Q1 2019

May 14, 2019

SELL
$45.12 - $53.8 $11,280 - $13,450
-250 Reduced 3.17%
7,628 $364,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $204,792 - $265,566
-4,200 Reduced 34.77%
7,878 $409,000
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $674,575 - $840,783
-13,350 Reduced 52.5%
12,078 $668,000
Q1 2018

May 17, 2018

SELL
$59.92 - $68.98 $142,310 - $163,827
-2,375 Reduced 8.54%
25,428 $1.61 Million
Q4 2017

Feb 15, 2018

SELL
$59.94 - $65.35 $107,892 - $117,629
-1,800 Reduced 6.08%
27,803 $1.7 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $1.63 Million - $1.89 Million
29,603
29,603 $1.89 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Doheny Asset Management /Ca Portfolio

Follow Doheny Asset Management /Ca and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

News

Stay updated on Doheny Asset Management /Ca with notifications on news.